Antonio Alvarado, MD
Nephrology · New Braunfels, TXNPI 1497076988
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $54,862 of the $78,275 with a category attached, or 70.1%. 25 manufacturers reported payments, led by Johnson & Johnson at 27.8% of the total. Reporting peaked in 2019 at $53,608 and has fallen 99.0% since, to $513 in 2025. Among nephrology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 380 payments — averaging $205.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$22K
- Vifor Pharma, Inc.$19K
- Otsuka America Pharmaceutical, Inc.$18K
- AstraZeneca$13K
- Akebia Therapeutics Inc$4K
- Amgen$384
- plus $2K from 19 others
What the payments were for
- Consulting fees$4,3506%
- Speaking & faculty fees$54,86270%
- Travel & lodging$11,76615%
- Food & beverage$7,1599%
- Education$1390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 20 | $21,788 |
| Vifor Pharma, Inc. | 71 | $19,020 |
| Otsuka America Pharmaceutical, Inc. | 67 | $17,656 |
| AstraZeneca(2 entities) | 70 | $13,306 |
| Akebia Therapeutics Inc | 23 | $4,142 |
| Amgen(2 entities) | 20 | $384 |
| Aurinia Pharma U.S., Inc. | 16 | $342 |
| OPKO Pharmaceuticals, LLC | 17 | $243 |
| Bayer | 12 | $201 |
| Ardelyx, Inc. | 11 | $176 |
| Boehringer Ingelheim | 8 | $167 |
| GSK | 5 | $87 |
| Travere Therapeutics, Inc. | 4 | $83 |
| AMAG Pharmaceuticals, Inc. | 5 | $82 |
| Mallinckrodt Hospital Products Inc. | 4 | $82 |
| Novartis | 4 | $81 |
| Fresenius USA Marketing, Inc. | 4 | $79 |
| Novo Nordisk | 3 | $71 |
| Gilead | 4 | $69 |
| Calliditas Therapeutics US Inc. | 4 | $66 |
| Lilly USA, LLC | 3 | $51 |
| Ultragenyx Pharmaceutical Inc. | 2 | $36 |
| Nxstage Medical, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$78,275 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 142 | $158,794 |
| VelphoroSucroferric Oxyhydroxide | 37 | $104,253 |
| XphozahTenapanor Hcl | 24 | $74,361 |
| JardianceEmpagliflozin | 40 | $53,313 |
| MounjaroTirzepatide | 37 | $45,653 |
| OzempicSemaglutide | 37 | $45,254 |
| VeltassaPatiromer Calcium Sorbitex | 24 | $28,244 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $20,307 |
| Sevelamer Carbonate | 45 | $13,456 |
| MyrbetriqMirabegron | 17 | $9,482 |
| Calcium Acetate | 55 | $3,635 |
| Bumetanide | 68 | $2,842 |
| Hydralazine Hcl | 112 | $1,736 |
| Nifedipine ErNifedipine | 90 | $1,617 |
| Losartan Potassium | 177 | $1,457 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $13,306 | $179,101154 claims |
| Fresenius USA Marketing, Inc.Velphoro | $79 | $104,25337 claims |
| Boehringer IngelheimJardiance | $167 | $53,31340 claims |
| Lilly USA, LLCMounjaro | $51 | $45,65337 claims |
| Novo NordiskOzempic | $71 | $45,25437 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,070 nephrology providers in Texas.
Other nephrology in New Braunfels
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
- Anand ReddyOdessa$469K
- Christopher KwohHouston$467K
- Wolfgang WinkelmayerHouston$462K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.